StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock analysis

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

StockData Score

Prices as of Nov 17, 2026How the score works

Value0Growth1Performance0Health2Dividend0

Weak3 of 30 checks passed

BioLineRx passes 3 of the 30 checks behind our score; 22 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
0/6
Financial health
2/6
Dividend
0/6

What stands out

  • Low debt

    Debt is 32.5% of shareholders' equity, under the 40% we consider low.

  • Gross margin improving

    Gross margin was 80.5% over the last twelve months, against 68.0% a year earlier.

  • Short-term assets cover short-term debts

    Current assets are 1.20 times current liabilities.

What to watch

  • Return on capital under 10%

    Return on invested capital was -59.7%, below the 10% that usually covers the cost of capital.

  • Interest not well covered

    Operating income covers interest expense -8.0 times; we look for at least 5.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -180% of total debt; we look for at least 20%.

  • Growing slower than the industry

    Revenue grew -95.9% over the last twelve months; the Drugs median is 6.5%.

Valuation0/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6
  • Revenue growth over 3 years

    Needs three years of positive revenue.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -95.9% over the last twelve months; the Drugs median is 6.5%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 80.5% over the last twelve months, against 68.0% a year earlier.

Past performance0/6
  • Return on equity

    Needs positive equity and five years of results.

  • Return on capital under 10%

    Return on invested capital was -59.7%, below the 10% that usually covers the cost of capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin against its history

    Needs five years of revenue and net income.

  • Net margin against the industry

    Needs revenue and net income.

Financial health2/6
  • Low debt

    Debt is 32.5% of shareholders' equity, under the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -180% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -8.0 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 1.20 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6
  • No dividend

    BioLineRx has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

We don't publish a fair value for BioLineRx. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$24.57K
Value traded per 1% price move
$5.96K

Downside

High risk

Typical loss in a bad month
30.4%
Volatility (annualized)
62%
Sharpe ratio, 1 year
-1.14
Beta to the S&P 500 (5Y)
1.56

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2014 to 2025

Gross margin

80.5%

Operating margin

-871.8%

See a number that looks wrong?